Home » Clavis, Clovis Sign $380 Million Partnership to Develop Anti-Cancer Agent
Clavis, Clovis Sign $380 Million Partnership to Develop Anti-Cancer Agent
Clavis Pharma ASA … and Clovis Oncology, Inc., … announced
an agreement for the further development and commercialization of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic
cancer.
Earth Times
Earth Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May